The startup develops an oral immunotherapy drug specifically targeting peanut allergies, utilizing a patient-centric approach to induce desensitization through controlled exposure. This treatment provides rapid bite-proof protection, enabling individuals with peanut allergies to significantly reduce their risk of allergic reactions and enhance their quality of life.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of individuals globally suffer from food allergies, with peanut allergy being a prevalent and severe condition. Current management strategies often involve strict avoidance and emergency medication, leading to anxiety and reduced quality of life due to the constant risk of accidental exposure and anaphylaxis. Existing oral immunotherapies (OIT) can cause frequent and severe side effects due to large, infrequent dose increases, requiring specialist supervision and frequent clinic visits.
Solution
Camallergy is a clinical-stage biopharmaceutical company developing patient-centric oral immunotherapy (OIT) treatments for food allergies, with an initial focus on peanut allergy. Their approach utilizes a novel dosage manager device that delivers precise, micro-doses of allergen, enabling daily up-dosing at home. This method aims to reduce the frequency and severity of side effects compared to traditional OIT protocols that involve large, less frequent dose escalations. By enabling smaller dose increments, Camallergy's technology seeks to improve the safety profile of OIT, reduce the treatment burden for both patients and physicians, and ultimately desensitize individuals to peanut allergens, providing protection against life-threatening allergic reactions. The treatment aims to retrain the immune system by promoting protective Treg cells and IgG4 antibodies while desensitizing mast cells and reducing IgE production.
Target Audience
The primary target audience includes individuals with peanut allergies, ranging from young children (1 year and older) to adults, and their families, as well as allergists and healthcare providers specializing in food allergy management.
Features
- Novel dosage manager device for precise delivery of micro-doses of peanut allergen
- Daily up-dosing regimen for at-home administration, eliminating the need for frequent clinic visits during the escalation phase
- Reduced dose increments compared to traditional OIT, aiming to minimize side effects
- Real-time monitoring of side effects and pre-programmed dose regimens to personalize treatment
- Oral immunotherapy desensitization to retrain the immune system and protect from life-threatening allergic reactions
- Characterized peanut flour used as the active pharmaceutical ingredient
- Based on clinical work initiated at Cambridge University Hospitals NHS Foundation Trust